Futura Medical plc

Equities

FUM

GB0033278473

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 06:44:10 2024-05-01 am EDT			5-day change	1st Jan Change
33.25 ^GBX	+0.91%		-6.47%	+30.39%

Apr. 10	Futura Medical hails results as erectile dysfunction drug drives sales	AN
Apr. 10	Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024

Futura Medical "absolutely delighted" with US commercialisation agreement

July 19, 2023 at 10:54 am EDT

(via NewsDirect)

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Thomas Warner from Proactive London after announcing the signing of an agreement with Haleon to market Futura's topical, gel-based erectile dysfunction treatment MED3000. Barder says he's absolutely delighted with the agreement, which gives Futura access to the world's largest market for erectile dysfunction treatments.

He gives a brief overview of the agreement, highlighting a $4 million upfront payment and milestone payments ranging from $5 million to $45 million. Barder emphasised the achievability of these milestones and mentioned that a royalty on all sales was also part of the agreement.

In related news, Futura Medical announced a change in leadership with Non-Executive Chairman John Clarke stepping down to be succeeded by existing Non-Executive board member, Jeff Needham. Barder says that Needham has "real, relevant experience as we look to launch in the biggest market in the world with MED3000."

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Futura Medical plc

Futura Medical hails results as erectile dysfunction drug drives sales	Apr. 10	AN
Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024	Apr. 10
Futura Medical plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Futura Medical's Eroxon to soon be available on prescription	Feb. 14	AN
BP and Prudential help snap FTSE losing streak	Feb. 06	AN
Futura Medical shares surge after "transformational year"	Feb. 06	AN
Futura Medical Extends License Deal with Cooper Consumer Health	Jan. 15	MT
Futura Medical extends licensing deal for erectile dysfunction gel	Jan. 15	AN
Futura Medical plc Extends Collaboration with Cooper Consumer Health	Jan. 15	CI
Futura Medical plc Announces Appointment of Roy Davis as Non-Executive Director	Jan. 09	CI
TRADING: Zambeef sees profit above market views; Luceco trades in line	Nov. 07	AN
Futura Medical, M8 Extend Deal to Offer Erectile Dysfunction Treatment in More Countries	Nov. 07	MT
Futura Medical, M8 Extend Deal to Offer Erectile Dysfunction Drug in More Countries	Nov. 07	MT
Futura Medical plc Expands Partnership with M8 Pharmaceuticals, Inc	Nov. 07	CI
Futura Medical gets Mexico marketing authorisation for Eroxon gel	23-10-25	AN
Eroxon® Granted Marketing Authorisation in Mexico	23-10-25	CI
Futura Medical launches erectile dysfunction gel in UAE	23-10-19	AN
UK’s Futura Medical Obtains EU Patent for Erectile Dysfunction Gel	23-10-02	MT
Futura Medical granted European patent for ED treatment	23-10-02	AN
Futura Medical plc Announces European Patent Office Grants Patent for Med3000	23-10-02	CI
Transcript : Futura Medical plc - Special Call	23-09-19
Elixirr record half-year revenue; Bango profit down	23-09-18	AN
Futura Medical plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-18	CI
Transcript : Futura Medical plc, H1 2023 Earnings Call, Sep 18, 2023	23-09-17
Futura Medical's ED treatment approved in Saudi Arabia	23-08-09	AN

Chart Futura Medical plc

Duration

Period

More charts

Company Profile

Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.

Sector

Biotechnology & Medical Research

Calendar

2024-09-10 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3295 GBP

Average target price

1.263 GBP

Spread / Average Target

+283.41%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FUTURA MEDICAL PLC	+30.39%	124M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.95%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs